Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer.
Osman KöstekN C DemircanA GökyerA KüçükardaB S SunalM B HacıoğluH EslameS SolakE YılmazS UzunoğluN TunçbilekI ÇiçinB ErdoğanPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2019)
Decrease in skeletal muscle mass before progression on CT imaging is an independent indicator for shorter PFS value in RAS WT mCRC patients who received anti-EGFR combined chemotherapy regimens at both the first and second-line settings. Beside that shorter overall survival values also were significantly seen in patients who had muscle loss during anti-EGFR therapy in the second-line setting.
Keyphrases
- skeletal muscle
- poor prognosis
- small cell lung cancer
- epidermal growth factor receptor
- tyrosine kinase
- metastatic colorectal cancer
- insulin resistance
- long non coding rna
- locally advanced
- high resolution
- stem cells
- squamous cell carcinoma
- type diabetes
- wild type
- adipose tissue
- radiation therapy
- free survival
- cell therapy